In this study we evaluated the impact of the tyrosine kinase receptor ligands VEGF-C, -D, AREG, EREG, as well as Hif-1 α, PTEN and of the VEGFR-3 on disease recurrence and survival in patients with CRC receiving adjuvant chemotherapy. This evidence concerns the gene FLT4 and colorectal carcinoma.